Serge Gauthier1, José L Molinuevo. 1. McGill Centre for Studies in Aging, Alzheimer's Disease Research Unit, Montreal, Quebec, Canada. serge.gauthier@mcgill.ca
Abstract
BACKGROUND: Clinical studies and post hoc analyses have investigated the use of combination therapy for the treatment of Alzheimer's disease (AD). We review the evidence for the short- and long-term efficacy of combination therapy in AD. METHODS: The review is based on a search of the PubMed database to identify relevant articles concerning combination treatment with memantine and cholinesterase inhibitors (ChEIs). RESULTS: In patients with moderate-to-severe AD, combination treatment with the N-methyl-d-aspartate receptor antagonist memantine and the ChEI donepezil has produced significant benefits in cognition, function, behavior, global outcome, and care dependency, compared with donepezil treatment alone. Data from long-term observational studies support these findings. Compared with ChEI monotherapy, combination treatment slowed cognitive and functional decline (a 4-year sustained effect that appeared to increase over time) and reduced the risk of nursing home admission. Preclinically, the combination of N-methyl-d-aspartate receptor modulation and acetylcholinesterase inhibition has been shown to act synergistically, which may explain the observed clinical effects of combination treatment. CONCLUSION: Treatment with memantine/ChEI combination therapy in moderate-to-severe AD produces consistent benefits that appear to increase over time, and that are beyond those of ChEI treatment alone.
BACKGROUND: Clinical studies and post hoc analyses have investigated the use of combination therapy for the treatment of Alzheimer's disease (AD). We review the evidence for the short- and long-term efficacy of combination therapy in AD. METHODS: The review is based on a search of the PubMed database to identify relevant articles concerning combination treatment with memantine and cholinesterase inhibitors (ChEIs). RESULTS: In patients with moderate-to-severe AD, combination treatment with the N-methyl-d-aspartate receptor antagonist memantine and the ChEI donepezil has produced significant benefits in cognition, function, behavior, global outcome, and care dependency, compared with donepezil treatment alone. Data from long-term observational studies support these findings. Compared with ChEI monotherapy, combination treatment slowed cognitive and functional decline (a 4-year sustained effect that appeared to increase over time) and reduced the risk of nursing home admission. Preclinically, the combination of N-methyl-d-aspartate receptor modulation and acetylcholinesterase inhibition has been shown to act synergistically, which may explain the observed clinical effects of combination treatment. CONCLUSION: Treatment with memantine/ChEI combination therapy in moderate-to-severe AD produces consistent benefits that appear to increase over time, and that are beyond those of ChEI treatment alone.
Authors: Daniel F Tardiff; Lauren E Brown; Xiaohui Yan; Richard Trilles; Nathan T Jui; M Inmaculada Barrasa; Kim A Caldwell; Guy A Caldwell; Scott E Schaus; Susan Lindquist Journal: ACS Chem Neurosci Date: 2017-07-12 Impact factor: 4.418
Authors: Javed Ahmad; Sohail Akhter; Md Rizwanullah; Mohammad Ahmed Khan; Lucie Pigeon; Richard T Addo; Nigel H Greig; Patrick Midoux; Chantal Pichon; Mohammad Amjad Kamal Journal: Curr Alzheimer Res Date: 2017 Impact factor: 3.498
Authors: G F Makhaeva; V V Grigoriev; A N Proshin; N V Kovaleva; E V Rudakova; N P Boltneva; I V Serkov; S O Bachurin Journal: Dokl Biochem Biophys Date: 2018-01-03 Impact factor: 0.788